𝗖𝗼𝗿𝗱𝗶𝘀

Cordis is a worldwide leader in the development & manufacturing of interventional vascular technology. This page shares content only for Healthcare professional

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Beyond efficacy, what truly drives your confidence in a drug-coated technology?

Join Dr. @AlokeFinn as he explores the evolution of DCB technology advancement from paclitaxel to sirolimus, comparing their pharmacokinetic profiles, mechanisms of action, and interactions within the coronary vasculature.

Watch at #VuMedi to gain practical insights that can help inform your clinical decision-making. https://t.co/6q3e8xhVGO

#InterventionalCardiology #PCI #MedicalEducation

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

A quarter of a million patients.

One philosophy: leave nothing behind.

More than 250,000 patients worldwide have now been treated with SELUTION SLR™ Drug-Eluting Balloon, our sustained-release sirolimus drug-eluting balloon — a milestone that reflects the growing clinical confidence in #DEBfirst strategies across coronary #PCI and peripheral intervention.

In a year defined by 250th milestones, ours is 250,000 reasons to keep advancing #InterventionalCardiology and endovascular care with technology designed to treat the lesion and leave no permanent implant behind.

To every physician, investigator, and patient that trusted the technology — thank you.

Explore the evidence behind #SELUTIONSLR https://t.co/ZDsH49J43Q

SELUTION SLR DEB is approved in the United States for investigational use only. Not available for commercial use.

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

@Christian091156 Congratulations to Dr. Spaulding and Dr. Eccleshall on this important publication. Advancing high-quality clinical evidence is critical to improving patient care and expanding treatment options for physicians worldwide.

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

✨ Now published in @American_Heart #Circulation: 12-month results from the SELUTION DeNovo randomized trial.

In 3,300+ patients across 62 international sites, a SELUTION SLR™ Drug-Eluting Balloon treatment strategy was non-inferior to systematic drug-eluting stent implantation for the study's primary endpoint at 12 months.

🔗https://t.co/E9kl79dtaE

#CordisGoBeyond #SELUTIONSLR #InterventionalCardiology

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Heading to #VAM2026? Stop by booth #510 to connect with the #Cordis team and learn how the MYNX CONTROL™ Vascular Closure Device can help support procedural efficiency and enhanced patient care.

Learn more: https://t.co/jC88qcqmfV

#CordisGoBeyond #EndovascularCare

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Congratulations to Joe DiPrima, VP of Information Technology, on receiving the 2026 South Florida CIO ORBIE Award for Enterprise.

The ORBIE Awards recognize technology leaders who drive innovation, business transformation, and measurable organizational impact. Selected by peer CIOs and technology executives, this recognition reflects Joe's leadership and the incredible work of our IT team and colleagues across the organization.

Please join us in congratulating Joe on this well-deserved recognition.

#Cordis #CordisGoBeyond

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

#Cordis is at #NCVH in New Orleans this week!

Stop by booth #222 to meet the team and learn how MYNX CONTROL® Vascular Care Device supports procedural excellence and patient care.

See where to connect with us next: https://t.co/zjJLOvIUgf

#CordisGoBeyond #EndovascularCare

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

In case you missed it 👇

EP programs across the U.S. are growing fast—are your workflows keeping up?

@Cordis partnered with Corazon to explore same-day discharge, recovery optimization & expanding EP capacity.

🎥 Watch on-demand:
https://t.co/iSHDmpMgEe

#CordisGoBeyond #Electrophysiology

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

SELUTION SLR™ PTA Drug-Eluting Balloon launches in Japan—introducing the country’s first sirolimus drug-eluting balloon. An important step in expanding access for physicians and patients.

Read the full release: https://t.co/LTOdLfl8PN

#CordisGoBeyond #PAD #SELUTIONSLR

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Great energy at #HRS2026 in Chicago—always inspiring to be with such a passionate EP community.

Thanks to all the #ePeeps who took a closer look at MYNX CONTROL™ Venous VCD—great questions and strong interest in practical venous closure solutions.

Learn more: https://t.co/MlSvKs0aeI

#CordisGoBeyond

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

🚨 New data presented by Dr.Michael Lichtenberg at #CX2026

In the SUCCESS study, freedom from clinically driven TLR was 86.1% at 24 months, representing a 5.3% change from 12 months in a combined claudicant and CLTI population.

View the full presentation here – https://t.co/t1MN22DKpD

#CordisGoBeyond #SELUTIONSLR #PAD

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Secure your spot—join our live EP webinar this Wednesday.

Join #Cordis & Corazon on April 22 to learn how leading U.S. EP programs are using same-day discharge (SDD) to improve efficiency + patient experience.

📅 Apr 22 | 12 PM ET

Register: https://t.co/pZqXifFUiN

#Electrophysiology #Cardiology

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

SELUTION4ISR 12-month results have been accepted in JACC.

In 418 ISR patients, SELUTION SLR™ DEB was non-inferior to standard care (DES/balloon; 80/20) for target lesion failure at 1 year.

Congrats to Drs. Cutlip & Mehran and global teams.

Read more: https://t.co/oNEtXitiTk

#JACC #InterventionalCardiology #ClinicalResearch #PCI #ISR

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

We were proud to host #FloridaInternationalUniversity Biomedical Engineering students at our Miami Lakes facility for a hands-on look inside Cordis.

From live catheter demos to tours of Manufacturing, Quality & R&D labs, they saw how innovation and teamwork drive better patient outcomes.

Inspiring the next generation of innovators.

https://t.co/3DZOe593tp

#CordisGoBeyond #engineers

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

At #HRS2026? Don’t miss our Skills Lab.

Hands-on with MYNX CONTROL VENOUS® VCD
📍 N229 · April 26
🕒 9:15 | 11:15 | 1:00 | 3:00 PM (CT)

Make time to join us on Saturday.

#Cordis #CordisGoBeyond

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Toronto here we come!

Join #Cordis at #SIR26TOR as we come together with the global interventional radiology community to discover what’s next.

Stop by booth #1400 to meet the team and learn more.

Find out where to connect with us this April: https://t.co/aeAsBCWotk

#CordisGoBeyond #InterventionalRadiology

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Don’t miss this SCAI sponsored CME dinner program, moderated by J. Dawn Abbott M.D. and Ron Waksman M.D

April 23 | 6:00–7:30 PM
Room 512ab, Level 5

Register: https://t.co/iCUGcDLxva

Supported by Cordis

#CordisGoBeyond #SCAI2026 #InterventionalCardiology

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

We’re heading to the Windy City.

Join #Cordis at #HRS2026 as we connect with the electrophysiology community and explore what’s next in cardiovascular care.

See where you can connect with us this April: https://t.co/zjJLOvIUgf

#CordisGoBeyond #EPeeps

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

On va à Montréal.

Join us at #SCAI2026 to connect with our team and explore Cordis-supported activities.

Learn more: https://t.co/qGp9DBiC4k

#CordisGoBeyond #InterventionalCardiology

[𝗖𝗼𝗿𝗱𝗶𝘀 @cordis]

Heading to the Big Easy for #ACC2026? 🎷

Meet the #Cordis team and learn how solutions like MYNX CONTROL® Vascular Closure Device, balloon catheter technologies, and the INFINITI® AMBI Diagnostic Catheter support interventional care.

Can’t make it? See where to connect with us next: https://t.co/aeAsBCWotk